

MEDIGARD

Dear Medigard Shareholder

My name is Ian Dixon and I am the new executive Director of Medigard Ltd.

Medigard (ASX-MGX) www.medigard.com.au is a listed company specialising in the research, development and commercialisation of medical technologies and developing new and innovative medical treatments.

My role is to help grow Medigard to become an important part of the Australian biotechnology sector. The Board and I are in the process of developing how we do this and expect to make some announcements soon.

Meanwhile, you can be assured that Medigard is continuing its proud position as an innovator in needle devices (syringes and blood collection devices) and is considering adding associated technologies such as pre-filled syringes and other needle device technologies/products that have improved margins and commercial prospects.

New technologies hold immense promise to solve unmet medical needs and build shareholder value. Often I meet Australian researchers who want to see their decades of work translated into real treatments. Previously, I have been successful in translating such research into valuable opportunities and products taken into clinical trials and I hope to apply my technological and commercial skills to your benefit.

Over the next few months we will ramp up a communications strategy and start to build a community around Medigard and its future. I can assure you that we will be working hard to build value for shareholders over the next 2-3 years.

Please follow our progress on your favourite channel, and feel free to contact me any time at ian.dixon@medigard.com.au phone + 613 9894 4555 (local 03 9894 4555) or mobile 0418 561 907.

Yours sincerely



Ian Dixon
Executive Director

13th December 2017